InMed Soars 100% on $290M Migraine Deal
InMed Pharmaceuticals shares jumped over 100% in busy Nasdaq trading Tuesday. The Vancouver drug developer said it will merge with private Mentari Therapeutics in an all-stock deal, aiming to bring the public company into migraine prevention therapies.
